biotech

Bio-Analyst

Research Platform
person
arrow_backExplore/Chromium
Tier-BPublic-ready7/3/2026

Chromium

Glucose and metabolic health markers is closer to a research marker, so it should be read separately from a directly felt benefit.

The 69.5 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the B tier remains conservative.

Representative tier calculated from paper evidence that passed the collection audit.

Papers analyzed
86
Caution signal
Low
Context-specific research signal
69.5
Glucose and metabolic health markersBlood pressure and vascular health markersStress Response and Sleep Changes

Main benefit evidence

The representative ingredient tier is calculated from these target-level evidence groups.

Glucose and metabolic health
18 studiesTier-B
Glucose and metabolic health markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
68.0
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood pressure and vascular health
1 studiesTier-C
Blood pressure and vascular health markers
Some positive signal observedResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
41.4
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Stress and mood
2 studiesTier-C
Stress Response and Sleep Changes
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.

Evidence score
34.8
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood lipids
6 studiesTier-C
Cholesterol and triglycerides
Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.

Evidence score
30.1
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Women's health
1 studiesTier-C
Menstrual and women's health
Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.

Evidence score
20.3
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Nutrient status and deficiency
2 studiesTier-C
Blood-Level or Deficiency Marker
Some positive signal observedResearch marker focusPatient-group study

This is based on lab markers such as blood levels, deficiency correction, or absorption. Read it separately from directly felt outcomes.

Evidence score
20.2
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Recent research

Updated This Month10 new papers

Observed range in repeated studies

This range includes studies in specific patient groups. It is not a general dose or recommendation.

Lower observed study value
100
mcg/day
Higher observed study value
1000
mcg/day
Only ranges repeated in human, oral, single-ingredient studies are shown.
Not personal dosing instructions, recommendations, or safety limits.

Side effects and combination findings in studies

Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.

Caution index
0.6
Caution band: Low
Caution signals
4
Side effects + combos + curated rules
Key precautions
No curated contraindication rule is available yet, but literature caution signals are shown below.
These are signals reported in studies. They do not predict what will happen to an individual.

Findings to review with care

Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.

Side effects reported when this ingredient was used alone

Symptoms or adverse events reported in studies of this ingredient without another active ingredient.

Adverse effect signal1 papers
Animal models exposed to chromium picolinate experienced degenerative changes in spermatogenesis.Human studies · Study type not identified
Adverse effect signal1 papers
Literature data pinpoints mechanisms of oxidative stress induced by chromium compounds in somatic and germ cells that lead to apoptosis, underlining the impairment of fertility potential.Human studies · Study type not identified
DNA damage1 papers
In db/db mice, prolonged treatment with high doses of chromium-picolinate resulted in high variability of DNA damage and dosage-dependent suppression of detoxification pathways, indicating potential individual toxicity risks.Animal studies · Study type not identified
Adverse effect signal1 papers
In a double-blind placebo-controlled trial, non-obese normoglycemic subjects receiving chromium picolinate 500 μg twice daily for 16 weeks showed no improvement in insulin sensitivity, and those with the highest serum chromium levels paradoxically experienced a decline in insulin sensitivity.Human studies · Study type not identified

Evidence summaries

Paper IDs and full lists are private. Only study types and summaries are shown.

Key Evidence #1
Public scholarly dataCitation signal: 338
rct

[Abstract]: To determine the effects of combined zinc (Zn) and chromium (Cr) supplementation on oxidative stress and glucose homeostasis of people with type 2 diabetes. Tunisian adult subjects with HbA1C > 7.5% were supplemented for 6 months with 30 mg/d of Zn

Key Evidence #2
Public scholarly dataCitation signal: 306
observational

It was concluded that the formulation having a coating level of 50% w/w of core and weight ratio of ethyl cellulose to Eudragit L 100 showed lesser release profile as compared to other formulation, as well as better entrapment of drug leading to controlled rel

Key Evidence #3
Public scholarly dataCitation signal: 281
meta-analysis

[Abstract]: Several authors, mostly on the basis of nonrandomized studies, have suggested dietary trivalent chromium supplementation as an attractive option for the management of type 2 diabetes and for glycemic control in persons at high risk of type 2 diabet

3 more summariesLimited representative sample by study type.
>
Public scholarly dataCitation signal: 136
meta-analysis

[Abstract]: The aim of this meta-analysis was to assess the evidence of chromium picolinate for reducing body weight. Literature searches were conducted on Medline, Embase, The Cochrane Library, Amed and Ciscom. Nine experts and four manufacturers of commercia

Public scholarly dataCitation signal: 108
rct

[Abstract]: Chromium is an essential nutrient involved in normal carbohydrate and lipid metabolism. It influences glucose metabolism by potentiating the action as taking part in insulin signal amplification mechanism. A placebo-controlled single blind, prospec

Public scholarly dataCitation signal: 105
rct

[Abstract]: OBJECTIVE To provide a comprehensive evaluation of chromium (Cr) supplementation on metabolic parameters in a cohort of Type 2 DM subjects representing a wide phenotype range and to evaluate changes in “responders” and “non-responders”. DESIGN Afte

Chromium
arrow_backBack to list